Entropy Technologies LP purchased a new stake in Tempus AI, Inc. (NASDAQ:TEM – Free Report) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 66,777 shares of the company’s stock, valued at approximately $3,943,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Tempus AI by 8.7% in the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after buying an additional 817,014 shares during the period. ARK Investment Management LLC boosted its position in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after buying an additional 381,816 shares during the period. GC Wealth Management RIA LLC purchased a new position in Tempus AI in the 4th quarter valued at approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 1.2% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company’s stock valued at $206,960,000 after buying an additional 41,728 shares during the period. Finally, Amova Asset Management Americas Inc. boosted its position in Tempus AI by 1.2% in the 4th quarter. Amova Asset Management Americas Inc. now owns 3,504,823 shares of the company’s stock valued at $206,960,000 after buying an additional 41,728 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.
Tempus AI Price Performance
Shares of TEM opened at $47.82 on Monday. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32. The stock has a market cap of $8.59 billion, a PE ratio of -27.80 and a beta of 3.64. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The firm has a fifty day moving average price of $49.32 and a 200 day moving average price of $56.69.
Analyst Ratings Changes
Several equities analysts have commented on the stock. TD Cowen raised their price target on shares of Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Wolfe Research assumed coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Jefferies Financial Group assumed coverage on shares of Tempus AI in a research report on Monday, April 13th. They issued an “underperform” rating and a $35.00 price target for the company. BTIG Research reissued a “buy” rating and issued a $80.00 price target on shares of Tempus AI in a research report on Monday, June 1st. Finally, Morgan Stanley decreased their price target on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Nine investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Tempus AI has a consensus rating of “Hold” and a consensus target price of $68.64.
View Our Latest Report on Tempus AI
Insider Buying and Selling
In other Tempus AI news, CAO Ryan M. Bartolucci sold 4,116 shares of Tempus AI stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $181,392.12. Following the transaction, the chief accounting officer directly owned 74,041 shares in the company, valued at approximately $3,262,986.87. The trade was a 5.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 13,550 shares of Tempus AI stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $597,148.50. Following the completion of the transaction, the chief executive officer owned 603,558 shares in the company, valued at approximately $26,598,801.06. This represents a 2.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 558,557 shares of company stock valued at $26,611,939 in the last quarter. Corporate insiders own 24.26% of the company’s stock.
Tempus AI Profile
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Articles
- Five stocks we like better than Tempus AI
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM – Free Report).
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
